Tumor News and Research

RSS

Response Genetics first-quarter total revenue up 140%

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results for the three months ended March 31, 2010.

14 May 2010

TechniScan awarded U.S. Patent for 3-D, Warm Bath Ultrasound system

A newly awarded U.S. Patent will protect TechniScan, Inc's., novel way to image, biopsy and treat breast cancer.

13 May 2010

Research article focuses on how IECs respond to probiotic strain B. lactis HN019

Probiotics are a group of live microorganisms administered in adequate amounts which confer a beneficial health effect on the host. This bacterial community plays a pivotal role in human nutrition and health by promoting the supply of nutrients, preventing pathogen colonization and shaping and maintaining normal mucosal immunity.

13 May 2010

Research investigates MDR in human HCC

Hepatocellular carcinoma responds poorly to chemotherapy owing to MDR. Recent studies have shown the tumors derived from the colon, kidney, or adrenal cortex, and HCC exhibited overexpression of MDR1/P-gp. This overexpression results in a primary MDR phenotype of these cancers.

13 May 2010

Researchers develop new approach to immunotherapy of cancer

Harnessing the immune system is emerging as one of the most promising new ways to fight cancer. Most cancer cells are eliminated by the immune system; however, over a lifetime, a few may escape this immune surveillance and lead to tumors and metastases. Hence a formidable opportunity has been to find ways to make the immune system recognize the tumor as a foreign body and trigger a response.

13 May 2010

Robotic surgery keeps features intact in head, neck cancer removal procedures

Surgeons who perform procedures to remove head and neck cancers often work for six to eight hours on what is typically major, invasive surgery, which many times comes with facial disfigurement and debilitating side effects for the patient.

13 May 2010

Four caged xanthones can inhibit growth of CCA cell lines: Research article

Cholangiocarcinoma is a malignant tumor, characterized by a poor prognosis and unresponsive to conventional chemotherapeutic agents. Therefore, searching for novel and effective therapeutic agents for CCA is necessary. In previous studies, several caged xanthones from G. hanburyi have been reported to be potent antiproliferatives as well as having anticancer and anti-tumor activities and they induce apoptosis in various cancer cell lines.

13 May 2010

Melanoma is becoming increasingly common: Mayo Clinic Women's HealthSource

Melanoma -- the most serious form of skin cancer -- is becoming increasingly common, according to the May issue of Mayo Clinic Women's HealthSource.

13 May 2010

FDA should apply equal rigor in assessing food claims and drug approvals, says new report

The U.S. Food and Drug Administration should apply the same rigor to evaluating the science behind claims of foods' and nutritional supplements' health benefits as it devotes to assessing medication and medical technology approvals, says a new report from the Institute of Medicine.

13 May 2010

CTI to conduct phase II study of pixantrone in patients with HER2-negative breast cancer

Cell Therapeutics, Inc. (CTI) today announced an agreement with the North Central Cancer Treatment Group (NCCTG) to conduct a phase II study of pixantrone in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens.

13 May 2010

Researchers develop new technology to manage prostate cancer treatment

Researchers at Queen's University have developed a new way of performing lab tests that could improve the way doctors manage prostate cancer treatment. It will allow them to identify with unprecedented accuracy losses of a gene called PTEN that is associated with an aggressive group of prostate cancers.

13 May 2010

Genetic tests represent future of cancer care for women

Important progress is being made in women's health through the use of genetic tests, particularly those that help women detect and treat cancer.

12 May 2010

Benefits outweigh risks in myeloablative therapy for children with high-risk neuroblastoma

Neuroblastoma is among the most common of childhood cancers and fortunately, some children will get better spontaneously. Yet for children with high-risk disease the outlook is poor: more than half will relapse despite chemotherapy.

12 May 2010

Gamma Knife stereotactic radiosurgery safe for treating children with arteriovenous malformations: Study

A new Mayo Clinic study has found that Gamma Knife™ stereotactic radiosurgery is a safe and effective option for selected children with arteriovenous malformations. This study was presented at the American Association of Neurological Surgeons Annual Meeting in Philadelphia last week.

12 May 2010

Response Genetics, GSK sign non-exclusive license agreement for BRAF mutational analysis technology

Response Genetics, Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced it has signed a non-exclusive license agreement with GlaxoSmithKline ("GSK"). Under the terms of the agreement, GSK gains certain rights to Response Genetics' proprietary PCR analysis technology and diagnostic expertise to assess BRAF gene mutations in human tumor samples. Payments will be made to Response Genetics upon achivement of agreed-to milestones.

12 May 2010

Angiogenesis inhibitors safe for cancer patients despite hypertension risk: Panel

A new class of cancer drugs can be used effectively while minimizing hypertensive side effects if patients' blood pressure is closely monitored and controlled, a clinical panel has determined.

12 May 2010

Oncos Therapeutics completes € 4 million investment from HealthCap

Oncos Therapeutics, a biotech company developing new cancer therapeutics based on its next generation oncolytic viruses, completed a € 4 million ($ 5.5 million) investment from HealthCap. With committed capital exceeding € 800 million, HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe.

12 May 2010

CEA-Leti launches TARGET-PDT project to increase effectiveness of PDT for treating cancer

CEA-Leti today announced the launch of the TARGET-PDT project designed to increase the effectiveness of photodynamic therapy for treating cancer by developing a novel nano carrier-based approach.

12 May 2010

CEVEC, Aragen Bioscience announce strategic license agreement

CEVEC Pharmaceuticals, the developer of a novel human expression system derived from amniocytes, and Aragen Bioscience, Inc., a California based contract research and development organization, announced today the signing of a strategic license agreement. This license enables Aragen Bioscience to offer its clients custom recombinant human cell lines expressing biotherapeutic proteins and antibodies as well as the transient and stable production of preclinical and clinical grade material.

12 May 2010

Exelixis first-quarter revenues increase to $42.2 million

Exelixis, Inc. today reported financial results for the first quarter ended March 31, 2010.

12 May 2010

Tumor News and Research

Response Genetics first-quarter total revenue up 140%

TechniScan awarded U.S. Patent for 3-D, Warm Bath Ultrasound system

Research article focuses on how IECs respond to probiotic strain B. lactis HN019

Research investigates MDR in human HCC

Researchers develop new approach to immunotherapy of cancer

Robotic surgery keeps features intact in head, neck cancer removal procedures

Four caged xanthones can inhibit growth of CCA cell lines: Research article

Melanoma is becoming increasingly common: Mayo Clinic Women's HealthSource

FDA should apply equal rigor in assessing food claims and drug approvals, says new report

CTI to conduct phase II study of pixantrone in patients with HER2-negative breast cancer

Researchers develop new technology to manage prostate cancer treatment

Genetic tests represent future of cancer care for women

Benefits outweigh risks in myeloablative therapy for children with high-risk neuroblastoma

Gamma Knife stereotactic radiosurgery safe for treating children with arteriovenous malformations: Study

Response Genetics, GSK sign non-exclusive license agreement for BRAF mutational analysis technology

Angiogenesis inhibitors safe for cancer patients despite hypertension risk: Panel

Oncos Therapeutics completes € 4 million investment from HealthCap

CEA-Leti launches TARGET-PDT project to increase effectiveness of PDT for treating cancer

CEVEC, Aragen Bioscience announce strategic license agreement

Exelixis first-quarter revenues increase to $42.2 million

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News